CD4 and infection: These results bare consequences for the quality and magnitude of T-cell priming during infection or cell-based therapy with DCs and as such hold promises for modifying CD4+ T-cell responses to BCG, other vaccines of low-to-modest efficacy, and to the implementation of adjunct therapies to infection and tumors.